Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Thomson, K. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomson, K. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 719-723
© 2000 The British Society for Antimicrobial Chemotherapy

Leading articles

Minimizing quinolone resistance: are the new agents more or less likely to cause resistance?

Kenneth S. Thomson*

Center for Research in Anti-Infectives and Biotechnology, Creighton University School of Medicine, Omaha, NE 68178, USA

The introduction of oral antimicrobial agents with broad-spectrum activity extending to methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa and other multiply antibiotic-resistant pathogens made the fluoroquinolones an attractive choice for empirical therapy for an extensive range of conditions. As a consequence there has been heavy and indiscriminate use of these agents in some centres1–6 resulting in fluoroquinolone resistance emerging more rapidly than anticipated in certain pathogens, especially those that were only marginally susceptible.3,4,7–9 With the recent releases of more potent agents such as trovafloxacin, grepafloxacin, sparfloxacin and levofloxacin, and others under development, there is now a concern that resistance to the newer agents may also develop. Two factors will be critical in determining the rate at which resistance to these agents develops—the manner in which fluoroquinolones (old and new) are used, and whether or not there are differences between the agents in their propensity to promote the development and spread of . . . [Full Text of this Article]

Prescribing behaviours and infection control

Ecologically preferred properties of fluoroquinolones

Pharmacokinetics

Potency

Dissociated fluoroquinolone resistance

Conclusion

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
H.-G. Wetzstein
Comparative Mutant Prevention Concentrations of Pradofloxacin and Other Veterinary Fluoroquinolones Indicate Differing Potentials in Preventing Selection of Resistance
Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4166 - 4173.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
F. J. Boswell, J. M. Andrews, G. Jevons, and R. Wise
Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance
J. Antimicrob. Chemother., October 1, 2002; 50(4): 495 - 502.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Hartman-Neumann, K. DenBleyker, L. A. Pelosi, L. E. Lawrence, J. F. Barrett, and T. J. Dougherty
Selection and Genetic Characterization of Streptococcus pneumoniae Mutants Resistant to the Des-F(6) Quinolone BMS-284756
Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2865 - 2870.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
H. Oh, N. El Amin, T. Davies, P. C. Appelbaum, and C. Edlund
gyrA Mutations Associated with Quinolone Resistance in Bacteroides fragilis Group Strains
Antimicrob. Agents Chemother., July 1, 2001; 45(7): 1977 - 1981.
[Abstract] [Full Text] [PDF]